Whitepaper on Tailoring Your Novel Therapeutic to ICER Standards

ICER (the Institute for Clinical and Economic Review) is an independent nonprofit organization dedicated to the fair evaluation of prescription drugs and other therapeutics, including medical devices. In its evaluations, it takes into account not only a drug’s efficacy, but also its cost relative to comparable drugs on the market (or lack therof). A negative evaluation can significantly affect a drug when it comes to market access and payer reimbursement decisions. A new whitepaper from Panalgo details steps that pharmaceutical companies can take when it comes to preparing for and improving an ICER evaluation.

“What is a pharmaceutical company to do when faced with an ICER assessment that can affect its pricing? One path is to challenge the decision during the designated public input period. Getting ICER to improve its evaluation, however, requires presenting significant and compelling data that bolsters the manufacturer’s case.” Read more here.

(Source: Matt Sussman, Panalgo, 11/19/20)